Difficulties in using 1,3-ß-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00051485" target="_blank" >RIV/00216224:14110/10:00051485 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1099/jmm.0.019299-0" target="_blank" >http://dx.doi.org/10.1099/jmm.0.019299-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1099/jmm.0.019299-0" target="_blank" >10.1099/jmm.0.019299-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Difficulties in using 1,3-ß-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis.

Popis výsledku v původním jazyce

We have evaluated the contribution of 1,3-ß-D-glucan (BG) assay for screening of invasive fungal diseases (IFI) in patients with hematological malignancies. Serum samples from patients at risk of IFI were collected twice a week and retrospectively testedusing the BG assay. BG screening was performed on 1143 samples from 91 patients during 104 anticancer treatment cycles. Proven and probable cases of IFI occurred in 9 (8.7%) treatment cycles. Depending on the criterion of positivity used (1&gt; 60 or 1&gt; 80 pg/ml and 2&gt; 60 or 2&gt; 80 pg/ml) the sensitivity was 89%, 89%, 67% and 44%. Although the test was marked as positive in 82%, 68%, 54% and 45% of all the treatment cycles, in the majority of cases, these positivities were probably false. The major limit of the BG test was extremely low PPV (10% to 12%). We have analyzed mucositis, candida colonization, bacteremia, using antimicrobials, erythrocyte and thrombocyte filtered blood products, collecting tubes or sampling via venous

Název v anglickém jazyce

Difficulties in using 1,3-ß-D glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis.

Popis výsledku anglicky

We have evaluated the contribution of 1,3-ß-D-glucan (BG) assay for screening of invasive fungal diseases (IFI) in patients with hematological malignancies. Serum samples from patients at risk of IFI were collected twice a week and retrospectively testedusing the BG assay. BG screening was performed on 1143 samples from 91 patients during 104 anticancer treatment cycles. Proven and probable cases of IFI occurred in 9 (8.7%) treatment cycles. Depending on the criterion of positivity used (1&gt; 60 or 1&gt; 80 pg/ml and 2&gt; 60 or 2&gt; 80 pg/ml) the sensitivity was 89%, 89%, 67% and 44%. Although the test was marked as positive in 82%, 68%, 54% and 45% of all the treatment cycles, in the majority of cases, these positivities were probably false. The major limit of the BG test was extremely low PPV (10% to 12%). We have analyzed mucositis, candida colonization, bacteremia, using antimicrobials, erythrocyte and thrombocyte filtered blood products, collecting tubes or sampling via venous

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Medical Microbiology

ISSN

0022-2615

e-ISSN

—

Svazek periodika

59

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

1016-1022

Kód UT WoS článku

000282117000003

EID výsledku v databázi Scopus

—